170 related articles for article (PubMed ID: 34799485)
1. Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.
Laurent C; Syrykh C; Hamon M; Adélaïde J; Guille A; Escudié F; Jalowicki G; Fina F; Bardet A; Mescam L; Molina TJ; Dartigues P; Parrens M; Sujobert P; Besson C; Birnbaum D; Xerri L
Am J Surg Pathol; 2022 Jun; 46(6):742-753. PubMed ID: 34799485
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
Jain MD; Ziccheddu B; Coughlin CA; Faramand R; Griswold AJ; Reid KM; Menges M; Zhang Y; Cen L; Wang X; Hussaini M; Landgren O; Davila ML; Schatz JH; Locke FL; Maura F
Blood; 2022 Aug; 140(5):491-503. PubMed ID: 35476848
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
5. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
6. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
7. Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization.
Wessendorf S; Schwaenen C; Kohlhammer H; Kienle D; Wrobel G; Barth TF; Nessling M; Möller P; Döhner H; Lichter P; Bentz M
Oncogene; 2003 Mar; 22(9):1425-9. PubMed ID: 12618769
[TBL] [Abstract][Full Text] [Related]
8. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
9. CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Ghilardi G; Braendstrup P; Chong EA; Schuster SJ; Svoboda J; Ruella M
Br J Haematol; 2021 May; 193(3):449-465. PubMed ID: 33222167
[TBL] [Abstract][Full Text] [Related]
10. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
11. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
[TBL] [Abstract][Full Text] [Related]
12. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
13. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.
Scholtysik R; Nagel I; Kreuz M; Vater I; Giefing M; Schwaenen C; Wessendorf S; Trümper L; Loeffler M; Siebert R; Küppers R
Int J Cancer; 2012 Sep; 131(5):E830-5. PubMed ID: 22213068
[TBL] [Abstract][Full Text] [Related]
14. Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.
Trecourt A; Mauduit C; Szablewski V; Fontaine J; Balme B; Donzel M; Laurent C; Sesques P; Ghesquières H; Bachy E; Salles G; Emile JF; Chassagne-Clément C; Genestier L; Copie-Bergman C; Traverse-Glehen A
Am J Surg Pathol; 2022 Jan; 46(1):58-70. PubMed ID: 34265801
[TBL] [Abstract][Full Text] [Related]
15. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract][Full Text] [Related]
16. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
Gerhard-Hartmann E; Rosenwald A
Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
[TBL] [Abstract][Full Text] [Related]
17. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
18. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
[TBL] [Abstract][Full Text] [Related]
19. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D
Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546
[No Abstract] [Full Text] [Related]
20. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
